1,721,160 research outputs found
Salaries and Participation
No full textThe income policy agreement of July 1993 - the so-called Accordo di Luglio - has considerably changed the industrial relations framework in Italy. The adoption of company agreements, linking workers’ compensation to company performance, opened up a new phase in bargaining, increasing the growth of decentralised negotiation between workers’ trade union organisations and companies. Previous empirical investigations have mainly analysed this phenomenon at national level, focussing on the factors behind this practice. Less attention has been devoted to the investigation of the diffusion of these negotiating practices at local level. The aim of this paper is to analyse this phenomenon at this level, investigating decentralised bargaining carried out in Italy. In particular, company bargaining on performance-related pay (PRP) and/or pay for participation (PFP) is analysed during the period 1994-1997 within this region. First of all, forms of agreement on PRP/PFP are investigated to find out the incentive, risk-sharing, and participation mechanisms as predicted by economic theory and embodied within each contract. Secondly, an econometric investigation is carried out to identify the variables which can explain their introduction
Presentazione al libro: Economia Internazionale. Globalizzazione, produzione e occupazione
No full textEconomia della Globalizzazione. Economia degli scambi e macroeconomia internazionale
No full textIl processo di globalizzazione dell’economia, ispirato ai principi della deregolamentazione e della flessibilità, ha costituito il carattere predominante del sistema delle relazioni economiche internazionali della nostra epoca. Il presente testo nasce dall’idea di offrire uno strumento utile per la comprensione delle cause, dei meccanismi in azione e delle possibili conseguenze dei processi di liberalizzazione e di globalizzazione dei mercati. Benché la finalità del volume sia prevalentemente didattica, l’obiettivo è anche quello di fornire una prospettiva di lettura e di interpretazione degli epifenomeni della globalizzazione sufficientemente aperta anche ad una visione critica dei processi, degli assetti istituzionali e delle opzioni di politica economica. Ciò soprattutto alla luce della evidente situazione di debolezza nella quale sembra versare oggi il modello di globalizzazione liberista, deregolata e senza governance che ha caratterizzato il sistema delle relazioni internazionali negli ultimi decenni
L’utilizzo di tecniche diagnostiche non invasive per la diagnosi precoce di tumori cutanei nei lavoratori outdoor
No full textThe emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
No full textThe promising new class of immunomodulating antibodies directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) has been extensively tested in clinical trials and found to be active against cutaneous melanoma and other tumor histotypes. Inhibition of CTLA-4 characteristically induces well-identified side effects for which the definition "immune-related adverse events" (irAEs) has been proposed. IrAEs mainly include colitis/diarrhea, dermatitis, hepatitis, and endocrinopathies; uveitis, nephritis, and inflammatory myopathy also have been reported occasionally. These unique side effects are likely a direct result of breaking immune tolerance upon CTLA-4 blockade and are generally mild, reversible, and manageable, following specific treatment guidelines that include symptomatic therapies or systemic corticosteroids. However, patientphysician communication and early treatment are also emerging as critical issues to successfully manage irAEs, thus avoiding major complications. The major experience in identifying and managing CTLA-4 treatment-related side effects has derived from studies in melanoma patients; nevertheless, accumulating clinical experiences are clearly demonstrating that irAEs are class-specific events, and that they are fully overlapping in patients with tumors of different histotypes. This review provides an overview of current safety data on CTLA-4 antagonists and of available strategies to optimize their clinical use in cancer patients
- …
